tradingkey.logo

2seventy bio rises on Bristol Myers buyout deal

ReutersMar 11, 2025 9:12 AM

Shares of cancer therapy maker 2seventy bio TSVT.O rise 76.07% to $4.93 premarket

Late on Monday, co said drugmaker Bristol Myers Squibb BMY.N to acquire all of the outstanding shares of TSVT at a price of $5.00 per share in an all-cash deal for a total equity value of about $286 million

The offer represents an 88% premium to TSVT's closing price of $2.66 on March 7

Deal expected to close in Q2 2025

TSVT is in partnership with BMY for CAR T cell therapy Abecma

TSVT shares fell ~31% in 2024

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI